Predicted protein targets (top 13)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | ALDH1A1 | P00352 | 1/20 | 0.52 |
| ▸ | NAAA | Q02083 | 1/20 | 0.52 |
| ▸ | FAAH | O00519 | 2/20 | 0.52 |
| ▸ | ATM | Q13315 | 1/20 | 0.48 |
| ▸ | HCAR2 | Q8TDS4 | 1/20 | 0.47 |
| ▸ | DGKA | P23743 | 1/20 | 0.47 |
| ▸ | HPGD | P15428 | 1/20 | 0.45 |
| ▸ | TSHR | P16473 | 1/20 | 0.45 |
| ▸ | RAD52 | P43351 | 1/20 | 0.44 |
| ▸ | NPSR1 | Q6W5P4 | 1/20 | 0.44 |
| ▸ | EPHX1 | P07099 | 1/20 | 0.44 |
| ▸ | ACHE | P22303 | 6/20 | 0.42 |
| ▸ | PAM | P19021 | 2/20 | 0.42 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL217404 | 0.98 | ALDH1A1 (0.54) | ALDH1A1NAAAFAAHATMHCAR2 | |
| SCHEMBL28059337 | 0.96 | ALDH1A1 (0.52) | ALDH1A1NAAAFAAHATMHCAR2 | |
| SCHEMBL3200912 | 0.96 | ALDH1A1 (0.52) | ALDH1A1NAAAFAAHATMHCAR2 | |
| Rubidium SCHEMBL3200922 | 0.96 | ALDH1A1 (0.52) | ALDH1A1NAAAFAAHATMHCAR2 | |
| Ammonia Solution, Strong SCHEMBL3204230 | 0.96 | ALDH1A1 (0.52) | ALDH1A1NAAAFAAHATMHCAR2 | |
| Hydrochloric Acid SCHEMBL10895277 | 0.96 | ALDH1A1 (0.52) | ALDH1A1NAAAFAAHATMHCAR2 | |
| SCHEMBL3187651 | 0.96 | ALDH1A1 (0.52) | ALDH1A1NAAAFAAHATMHCAR2 | |
| SCHEMBL27407560 | 0.96 | ALDH1A1 (0.52) | ALDH1A1NAAAFAAHATMHCAR2 | |
| SCHEMBL27693150 | 0.96 | ALDH1A1 (0.52) | ALDH1A1NAAAFAAHATMHCAR2 | |
| Butane SCHEMBL9473129 | 0.94 | NAAA (0.61) | NAAAFAAHHCAR2DGKATSHR |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 153 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| CN-117700654-A | Copolyester for weather-resistant coating and preparation method and application thereof | 中瀚新材料科技有限公司 | 2024-03-15 | — | — | CN | claimed |
| EP-0674233-B1 | Recording sheets | XEROX CORP (US) | 2000-05-24 | — | — | EP | claimed |
| US-5928765-A | Recording sheets | XEROX CORPORATION (US) | 1999-07-27 | — | — | US | claimed |
| EP-0674233-A2 | Recording sheets | XEROX CORPORATION (US) | 1995-09-27 | — | — | EP | claimed |
| JP-8269036-A | — | — | None | — | — | JP | disclosed |
| US-20240191594-A1 | Cement Top Jobs In Wellbore Annuli Using Expandable Compositions | CHEVRON U.S.A. INC. | 2024-06-13 | — | — | US | disclosed |
| CN-117700654-A | Copolyester for weather-resistant coating and preparation method and application thereof | 中瀚新材料科技有限公司 | 2024-03-15 | — | — | CN | disclosed |
| US-11884624-B2 | Difluorolactam compounds as EP4 receptor-selective agonists for use in the treatment of EP4-mediated diseases and conditions | CAYMAN CHEMICAL COMPANY, INC. (US) | 2024-01-30 | — | — | US | disclosed |
| US-20240026749-A1 | DEPLOYMENT METHODS FOR EXPANDABLE POLYMER GROUT FOR PLUG AND ABANDONMENT APPLICATIONS | CHEVRON AUSTRALIA PTY LTD (AU) | 2024-01-25 | — | — | US | disclosed |
| US-20240026206-A1 | METHODS OF USING EXPANDABLE POLYMER GROUT FOR PLUG AND ABANDONMENT APPLICATIONS | CHEVRON AUSTRALIA PTY LTD (AU) | 2024-01-25 | — | — | US | disclosed |
| US-20230233500-A1 | Gasdermin D (GSDMD) Succination for the Treatment of Inflammatory Disease | UNIVERSITY OF MASSACHUSETTS | 2023-07-27 | — | — | US | disclosed |
| CN-116474766-A | Cerium oxide loaded manganese-zinc oxide catalyst, preparation method and method for preparing malonate derivative by using cerium oxide loaded manganese-zinc oxide catalyst | 万华化学集团股份有限公司 | 2023-07-25 | — | — | CN | disclosed |
| US-5451458-A | Electrography | XEROX CORPORATION (US) | 1995-09-19 | — | — | US | disclosed |
| US-5438110-A | Homopolymerizing or copolymerizing olefins in presence of catalyst formed from solid component containing titanium, magnesium, halogen, electron donor, organoaluminum compound, organosilicon compound having cyclopentyl group | MITSUI PETROCHEMICAL INDUSTRIES, LTD. (JP) | 1995-08-01 | — | — | US | disclosed |
| EP-0350170-B1 | Process for polymerising olefins and polymerisation catalyst therefor | MITSUI PETROCHEMICAL IND (JP) | 1994-03-02 | — | — | EP | disclosed |
| US-4990479-A | Coordination catalysts | MITSUI PETROCHEMICAL INDUSTRIES, LTD. (JP) | 1991-02-05 | — | — | US | disclosed |
| EP-0385765-A2 | Process for polymerizing olefins and catalyst for polymerizing olefins | MITSUI PETROCHEMICAL INDUSTRIES, LTD. (JP) | 1990-09-05 | — | — | EP | disclosed |
| EP-0350170-A2 | Process for polymerising olefins and polymerisation catalyst therefor | MITSUI PETROCHEMICAL INDUSTRIES, LTD. (JP) | 1990-01-10 | — | — | EP | disclosed |
| EP-0282341-A1 | Process for polymerization of olefins and polymerization catalyst | MITSUI PETROCHEMICAL INDUSTRIES, LTD. (JP) | 1988-09-14 | — | — | EP | disclosed |
| US-4036985-A | Mono substituted malonic acid diamides and process of preparing them | AMATO JOSE | 1977-07-19 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-11884624-B2 | Difluorolactam compounds as EP4 receptor-selective agonists for use in the treatment of EP4-mediated diseases and conditions | PTGER4, PTGER1, PTGER3 | ALDH1A1 654/4885NAAA 3061/4885FAAH 240/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.